Cure My Disease

Don't miss your cure!

 Log in / Sign up

AML drug venetoclax under Real-World watch in south korea

NCT ID NCT04826523

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers tracked side effects and how well the cancer responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Venetoclax (Venclexta) tablets
What this could lead to
If successful, this study will confirm that venetoclax is a safe and effective treatment option for AML in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like serious infections or low blood counts are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

  • Chonnam National University Hwasun Hospital /ID# 257478

    Hwasun-gun, Jeonranamdo, 58128, South Korea

  • Gachon University Gil Medical Center /ID# 239008

    Incheon, Gyeonggido, 21565, South Korea

  • Korea University Anam Hospital /ID# 231022

    Seoul, Seoul Teugbyeolsi, 02841, South Korea

  • Kosin University Gospel Hospital /ID# 257399

    Busan, Busan Gwang Yeogsi, 49267, South Korea

  • Kyungpook National University Hospital /ID# 257398

    Daegu, Daegu Gwang Yeogsi, 41944, South Korea

  • Pusan National University Hospital /ID# 239010

    Busan, Busan Gwang Yeogsi, 49241, South Korea

  • Samsung Medical Center /ID# 239009

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 257477

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Yeungnam University Medical Center /ID# 239007

    Daegu, 42415, South Korea

  • Yonsei University Health System Severance Hospital /ID# 239006

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.